REGENERAProject ID: 736357
H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
REGENERATING NATURAL AESTHETICS
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs
Call for proposal:H2020-SMEINST-1-2016-2017See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
Every Year, globally ca. 0.8 million people experience reconstructive surgery after mastectomy or lumpectomy and 1.2 million undergo breast augmentation surgery. Currently, breast defects are not properly reconstructed but only temporary filled with silicone implants, which however present several drawbacks such as the need of substitution after approximately 10 years, rupture (30% of incidence), leakage and capsular contracture. An alternative procedure that is currently available in clinics is fat autotransplantation. However, this technique presents potential carcinogenic risks and is still limited to small volumes, requiring multiple interventions to achieve larger reconstructions.
REGENERA is an innovative mammary prosthesis based on biodegradable, porous, synthetic biomaterials and manufactured with internal micro-channels replicating the blood-vessels architecture. This distinctive combination, obtained by a patented process, promotes the natural fat growth, and allows the regeneration of a large adipose tissue volume. REGENERA’s overall objective is to improve patients’ quality of life, by restoring permanently the breast’s natural shape, appearance and size following a mastectomy/lumpectomy. Moreover, since REGENERA does not require further surgical operations for the rest of the patient’s life, it can drastically reduce the pain of the patient and decrease the associated Healthcare costs.
REGENERA specific objective is to provide a biocompatible support able to induce the ingrowth of adipocytes and subsequently degrade, allowing the complete maturation of a stable adipose tissue, that replaces the original volume occupied by the prosthesis.
EU contribution: EUR 50 000
VIA TIMAVO 34